Hadasit Bio-Holdings
Edit Page
Report
Scan day: 05 February 2014 UTC
13
Virus safety - good
Description: Provider of plasma-based products in the fields of regenerative medicine, oncology, and auto-immune diseases.
Investing in Hadassah Based Biotech Companies Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) in order to allow public participation in the promising field of biotechnology. It serves as a precedent in biotechnology financing - for the first time, public investment is allowed to participate in companies based on IP generated by Israel's foremost medical research center - the Hadassah University Hospital ("Hadassah"), which is responsible for the majority of Israel's hospital-based translational research.
Size: 593 chars
Contact Information
Email: —
Phone&Fax: —
Address: —
Extended: —
WEBSITE Info
| Page title: | Hadasit Bio-Holdings |
| Keywords: | Hadasit Bio-Holdings Ltd. (HBL) was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the promising field of biotechnology. It serves as a precedent in biotechnology financing - for the first time, public investment is allowed to participate in companies based on IP generated by Israel's foremost medical research center the Hadassah University Hospital (Hadassah). Investments Biotechnology Israel Life Sciences Early Stage companies ILSI Peptides small molecules Hadasit Bio Holdings enables a diversified investment in Israeli biotech companies at stages ranging from start up with proof of concept in animals to companies with products and drugs in human clinical trials phase I and phase II. pharmaceutical drugs and treatments are being developed in the areas of cancer, tissue regeneration with stem cells and auto immune diseases, all fields where the Hadassah medical centers of research and innovation excel and have a world renowned name as leaders in the field. biotech biotech industry biotech business biotechnology company biotechnology research biomedical technology phase i clinical trial phase ii clinical trial |
| Description: | Hadasit Bio-Holdings, Ltd. (HBL) (TASE: HDST , OTCBB: HADSY) sets a precedent in biotechnology financing by allowing public investment in companies based on IP generated by Israel's foremost medical research center the Hadassah University Hospital. HBL focuses on advancing companies that have already shown proof of concept and successful preclinical trials to completion of Phase I/II. |
| IP-address: | 82.80.247.30 |